Upstart Co-founder and CEO to Participate in Fireside Chat at the Goldman Sachs Communacopia and Technology Conference 2026

Upstart Co-founder and CEO to Participate in Fireside Chat at the Goldman Sachs Communacopia and Technology Conference 2026

BURLINGAME, Calif.–(BUSINESS WIRE)–
Upstart Holdings, Inc. (NASDAQ: UPST), the leading artificial intelligence (AI) lending marketplace, today announced that Paul Gu, Co-founder and CEO, will participate in a fireside chat at the Goldman Sachs Communacopia and Technology Conference on Tuesday, September 8, at 11:30 am PT (2:30 pm ET).

A live audio webcast of the event will be available on Upstart’s investor relations website at ir.upstart.com. A replay of the webcast will be available for a limited period of time following the event.

About Upstart

Upstart (NASDAQ: UPST) is the leading AI lending marketplace, connecting millions of consumers to more than 100 banks and credit unions that leverage Upstart’s AI models and cloud applications to deliver superior credit products. With Upstart AI, lenders can approve more borrowers at lower rates while delivering the exceptional digital-first experience customers demand. More than 90% of loans are fully automated, with no human intervention by Upstart. Founded in 2012, Upstart’s platform includes personal loans, automotive loans, home equity lines of credit, and Upstart’s new Cash Line product, a revolving line of credit. Upstart is based in Burlingame, California.

Investors

Sonya Banerjee

[email protected]

Press

Eric Smith

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Technology Software Finance Artificial Intelligence Internet Banking

MEDIA:

Logo
Logo

Zeta Global to Participate in Upcoming Investor Conferences

Zeta Global to Participate in Upcoming Investor Conferences

NEW YORK–(BUSINESS WIRE)–
Zeta Global (NYSE: ZETA), the intelligent AI infrastructure company, today announced that it is scheduled to participate in the following investor conferences:

Date

Conference

September 8

Goldman Sachs Communacopia + Technology Conference*

September 9

Citi 2026 Global TMT Conference*

*Live webcast and replay of this presentation will be accessible on Zeta’s Investor Relations website at investors.zetaglobal.com where it will remain available for 1 year.

About Zeta

Zeta Global (NYSE: ZETA) is the intelligent AI infrastructure company helping enterprises transform proprietary data into enterprise intelligence. The Zeta Data Cloud and Athena by Zeta™ connect proprietary enterprise knowledge with advanced AI to enable better decisions, more effective customer engagement, and stronger business outcomes. With one of the industry’s largest proprietary data assets, Zeta helps organizations accelerate AI transformation and build durable competitive advantage. Founded in 2007 by David A. Steinberg and John Sculley, Zeta is headquartered in New York City with offices worldwide. Learn more at www.zetaglobal.com.

Investor Relations

Trey Campbell

[email protected]

Press

Krystina Puleo

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Software Mobile/Wireless Internet Professional Services Technology Artificial Intelligence Publishing Data Analytics Marketing Advertising Communications Finance

MEDIA:

Logo
Logo

Semtech Announces Second Quarter of Fiscal Year 2027 Results

Semtech Announces Second Quarter of Fiscal Year 2027 Results

  • Record net sales of $341.9 million, up 17% sequentially and up 33% year-over-year

  • GAAP gross margin of 53.8% and Non-GAAP adjusted gross margin of 54.5%

  • GAAP operating margin of 16.3% and Non-GAAP adjusted operating margin of 24.4%

  • GAAP diluted earnings per share of $1.59 and Non-GAAP adjusted diluted earnings per share of $0.71

CAMARILLO, Calif.–(BUSINESS WIRE)–
Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, announced today unaudited financial results for its second quarter of fiscal year 2027, which ended July 26, 2026.

“The Semtech team executed exceptionally well, delivering record revenue across our key focus areas, earnings leverage that continued to outpace revenue growth and significant progress on portfolio optimization,” said Hong Hou, president and CEO. “Accelerating bookings and record backlog point to a strong inflection in growth with new revenue drivers and visibility expected to extend well into next fiscal year. Growing our focus areas and expanding margins all serve the same goal: building a predictable, high-margin and high-return business.”

“This was another quarter of disciplined execution, converting record revenue, margin expansion and diluted earnings per share growth into strong operating and free cash flow,” said Mark Lin, executive vice president and chief financial officer. “We enter the third quarter with conviction, expecting broad-based bookings strength to translate into sustained revenue, margin and earnings growth.”

Second Quarter of Fiscal Year 2027 Results

(in millions, except per share data)

Q2’27

 

Q1’27

 

Q2’26

GAAP Financial Results

 

 

 

 

 

Net sales

$

341.9

 

 

$

291.0

 

 

$

257.6

 

Gross margin

 

53.8

%

 

 

52.0

%

 

 

52.1

%

Operating expenses, net

$

128.0

 

 

$

125.7

 

 

$

150.3

 

Operating income (loss)

$

55.8

 

 

$

25.8

 

 

$

(16.2

)

Operating margin

 

16.3

%

 

 

8.9

%

 

 

(6.3

)%

Interest expense, net

$

1.0

 

 

$

1.0

 

 

$

4.7

 

Goodwill impairment

$

 

 

$

 

 

$

42.0

 

Net income (loss)

$

160.1

 

 

$

26.6

 

 

$

(27.1

)

Diluted earnings (loss) per share

$

1.59

 

 

$

0.27

 

 

$

(0.31

)

 

 

 

 

 

 

(in millions, except per share data)

Q2’27

 

Q1’27

 

Q2’26

Net sales

$

341.9

 

 

$

291.0

 

 

$

257.6

 

Non-GAAP Financial Results

 

 

 

 

 

Adjusted gross margin*

 

54.5

%

 

 

53.0

%

 

 

53.2

%

Adjusted operating expenses, net*

$

102.8

 

 

$

95.1

 

 

$

88.4

 

Adjusted operating income*

$

83.6

 

 

$

59.3

 

 

$

48.6

 

Adjusted operating margin*

 

24.4

%

 

 

20.4

%

 

 

18.8

%

Adjusted interest (income) expense, net*

$

(0.2

)

 

$

(0.1

)

 

$

4.1

 

Adjusted net income*

$

69.5

 

 

$

49.4

 

 

$

36.7

 

Adjusted diluted earnings per share*

$

0.71

 

 

$

0.51

 

 

$

0.41

 

Adjusted EBITDA*

$

91.1

 

 

$

66.4

 

 

$

56.5

 

Adjusted EBITDA margin*

 

26.6

%

 

 

22.8

%

 

 

21.9

%

*See “Non-GAAP Financial Measures” below for additional information about our non-GAAP financial results.

Third Quarter of Fiscal Year 2027 Outlook

(in millions, except per share data)

 

Net sales

$

410.0

 

 

+/-

 

$5.0

Non-GAAP Financial Measures

 

 

 

 

 

Adjusted gross margin*

 

58.3

%

 

+/-

 

100 bps

Adjusted gross margin, excluding business held for sale*

 

63.9

%

 

+/-

 

100 bps

Adjusted operating expenses, net*

$

112.0

 

 

+/-

 

$3.0

Adjusted operating income*

$

127.0

 

 

+/-

 

$4.0

Adjusted operating margin*

 

31.0

%

 

+/-

 

60 bps

Adjusted interest and other expense, net*

$

0.5

 

 

 

 

 

Adjusted normalized tax rate*

 

18

%

 

 

 

 

Adjusted diluted earnings per share*

$

1.05

 

 

+/-

 

$0.03

Adjusted EBITDA*

$

134.3

 

 

+/-

 

$4.0

Adjusted EBITDA margin*

 

32.8

%

 

+/-

 

60 bps

 

 

 

 

 

 

Non-GAAP diluted share count*

 

99.0

 

 

 

 

 

*See “Non-GAAP Financial Measures” below for additional information about our non-GAAP financial results.

 

The Company is unable to include a reconciliation of forward-looking non-GAAP results to the corresponding GAAP measures as they are not available without unreasonable efforts due to the high variability and low visibility with respect to the impact of transaction, integration and restructuring expenses, share-based awards, amortization of acquisition-related intangible assets and other items that are excluded from these non-GAAP measures. The Company expects the variability of the above charges to have a potentially significant impact on its GAAP financial results.

Webcast and Conference Call

Semtech will be hosting a conference call today to discuss its second fiscal quarter 2027 results at 1:30 p.m. Pacific time. The dial-in number for the call is (877) 407-0312. Please use conference ID 13761388. An audio webcast and supplemental earnings materials for the quarter will be available on the Investor Relations section of Semtech’s website at investors.semtech.com under “News & Events.” A replay of the call will be available through September 22, 2026 at the same website or by calling (877) 660-6853 and entering conference ID 13761388.

Non-GAAP Financial Measures

To supplement the Company’s consolidated financial statements prepared in accordance with GAAP, this release includes a presentation of select non-GAAP financial measures. The Company’s non-GAAP measures of adjusted gross margin, total semiconductor products gross margin, adjusted gross margin, excluding business held for sale, adjusted product development and engineering expense, adjusted selling, general and administrative expense, adjusted operating expenses, net, adjusted operating income, adjusted operating margin, adjusted interest (income) expense, net, adjusted net income, adjusted diluted earnings per share, adjusted normalized tax rate, adjusted EBITDA and adjusted EBITDA margin exclude the following items, if any and as applicable, as set forth in the reconciliations in the tables below under “Supplemental Information: Reconciliation of GAAP to Non-GAAP Results.”

  • Share-based compensation

  • Intangible amortization

  • Transaction and integration related costs or recoveries

  • Restructuring and other reserves, including cumulative other reserves associated with historical activity including environmental, pension, deferred compensation and right-of-use asset impairments

  • Litigation costs or dispute settlement charges or recoveries

  • Equity method income or loss

  • Investment gains, losses, reserves and impairments, including interest income from debt investments

  • Write-off and amortization of deferred financing costs

  • Interest rate swap termination

  • Induced conversion expense

  • Loss on extinguishment of debt

  • Debt commitment fee

  • Goodwill and intangible impairment

  • Amortization of inventory step-up

In this release, the Company is providing a total semiconductor products gross margin metric, defined as the combined segment gross margin for the Signal Integrity and Analog Mixed Signal and Wireless reportable segments. For further information, please see the Segment Information footnote of the Company’s Form 10-Q for the quarter ended July 26, 2026. The Company is also providing an adjusted gross margin, excluding business held for sale metric, defined as adjusted gross margin excluding the results of the Company’s cellular module business, classified as held for sale as of period end. The Company also presents adjusted EBITDA, adjusted EBITDA margin and free cash flow. Adjusted EBITDA is defined as net income (loss) plus interest expense, interest income, (benefit) provision for income taxes, depreciation and amortization, and share-based compensation, and adjusted to exclude certain expenses, gains and losses that the Company believes are not indicative of its core results over time. Adjusted EBITDA margin is defined as adjusted EBITDA as a percentage of net sales. The Company considers free cash flow, which may be positive or negative, a non-GAAP financial measure defined as cash flows provided by operating activities less net capital expenditures. Management believes that the presentation of these non-GAAP measures provides useful information to investors regarding the Company’s financial condition and results of operations. These non-GAAP financial measures are adjusted to exclude the items identified above because such items are either operating expenses that would not otherwise have been incurred by the Company in the normal course of the Company’s business operations, or are not reflective of the Company’s core results over time. These excluded items may include recurring as well as non-recurring items, and no inference should be made that all of these adjustments, charges, costs or expenses are unusual, infrequent or non-recurring. For example: certain restructuring and integration-related expenses (which consist of employee termination costs, facility closure or lease termination costs, and contract termination costs) may be considered recurring given the Company’s ongoing efforts to be more cost effective and efficient; certain acquisition and disposition-related adjustments or expenses may be deemed recurring given the Company’s regular evaluation of potential transactions and investments; and certain litigation expenses or dispute settlement charges or gains (which may include estimated losses for which the Company may have established a reserve, as well as any actual settlements, judgments, or other resolutions against, or in favor of, the Company related to litigation, arbitration, disputes or similar matters, and insurance recoveries received by the Company related to such matters) may be viewed as recurring given that the Company may from time to time be involved in, and may resolve, litigation, arbitration, disputes, and similar matters.

Notwithstanding that certain adjustments, charges, costs or expenses may be considered recurring, in order to provide meaningful comparisons, the Company believes that it is appropriate to exclude such items because they are not reflective of the Company’s core results and tend to vary based on timing, frequency and magnitude.

These non-GAAP financial measures are provided to enhance the user’s overall understanding of the Company’s comparable financial performance between periods. In addition, the Company’s management generally excludes the items noted above when managing and evaluating the performance of the business. Certain non-GAAP financial measures are also used in the Company’s compensation programs. The financial statements provided with this release include reconciliations of these non-GAAP financial measures to their most comparable GAAP measures for the first and second quarters of fiscal year 2027 and the second quarter of fiscal year 2026.

The Company adopted a full-year, normalized tax rate for the computation of the non-GAAP income tax provision in order to provide better comparability across the interim reporting periods by reducing the quarterly variability in non-GAAP tax rates that can occur throughout the year. In estimating the full-year non-GAAP normalized tax rate, the Company utilized a full-year financial projection that considers multiple factors such as changes to the Company’s current operating structure, existing positions in various tax jurisdictions, the effect of key tax law changes, and other significant tax matters to the extent they are applicable to the full fiscal year financial projection. In addition to the adjustments described above, this normalized tax rate excludes the impact of share-based awards and the amortization of acquisition-related intangible assets. For the first two quarters of fiscal year 2027, the Company applied a non-GAAP normalized tax rate of 17%. For the remaining quarters of fiscal year 2027, the Company’s projected non-GAAP normalized tax rate is 18%. The Company’s non-GAAP normalized tax rate on non-GAAP net income may be adjusted during the year to account for events or trends that the Company believes materially impact the original annual non-GAAP normalized tax rate including, but not limited to, significant changes resulting from tax legislation, acquisitions, entity structures or operational changes and other significant events. These additional non-GAAP financial measures should not be considered substitutes for any measures derived in accordance with GAAP and may be inconsistent with similar measures presented by other companies.

To provide additional insight into the Company’s third quarter outlook, this release also includes a presentation of forward-looking non-GAAP financial measures. See “Third Quarter of Fiscal Year 2027 Outlook” above for further information.

Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, as amended, based on the Company’s current expectations, estimates and projections about its operations, industry, financial condition, performance, results of operations, and liquidity. Forward-looking statements are statements other than historical information or statements of current condition and relate to matters such as future financial performance including the third quarter of fiscal year 2027 outlook; future operational performance; the anticipated impact of specific items on future earnings; the Company’s expectations regarding near term growth trends and market position; and the Company’s plans, objectives and expectations. Statements containing words such as “may,” “believes,” “see,” “anticipates,” “expects,” “intends,” “positions,” “plans,” “targets,” “projects,” “objectives,” “estimates,” “develops,” “should,” “could,” “will,” “designed to,” “projections,” or “outlook,” or other similar expressions constitute forward-looking statements.

Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results and events to differ materially from those projected. Potential factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: the volatility of our financial results or impact of the cyclical nature of our industry, including due to a growing concentration of demand in artificial intelligence-related semiconductors, during industry downturns or due to periodic economic uncertainty; the historical rapid decrease of the average selling prices of certain products; disruptions in U.S. or foreign government operations, funding or incentives; changes in export restrictions and laws affecting the Company’s trade and investments, including tariffs or retaliatory tariffs; interruption or loss of supplies or services from the limited number of suppliers and subcontractors we rely upon; our suppliers’ manufacturing capacity constraints or other supply chain disruptions; failure to successfully develop and sell new products, meet new industry standards or requirements or anticipate changes in projected or end market users; failure to adequately protect our intellectual property rights; failure to make the substantial investments in research and development that are required to remain competitive in our business or to properly anticipate competitive changes in the marketplace; the likelihood of our products being found defective or risk of liability claims asserted against us; business interruptions, such as natural disasters, acts of violence and the outbreak of contagious diseases; adverse changes to general economic conditions in China; the loss of any one of our small number of customers or failure to collect a receivable from them; competition from new or established IoT, cloud services and wireless service companies or from those with greater resources; the difficulties associated with integrating ours and Sierra Wireless, Inc.’s businesses and operations successfully as well as difficulties executing other acquisitions or divestitures, including the pending divestiture of our cellular module business and attendant risks; discovery of additional material weaknesses in our internal control over financial reporting in the future or otherwise failing to achieve and maintain effective disclosure controls, procedures and internal control over financial reporting; changes in our effective tax rates, the adoption of new U.S. or foreign tax legislation or exposure to additional tax liabilities, or material differences between our forecasted annual effective tax rates and actual tax rates; the Company’s ability to comply with, or pursue business strategies due to, our level of indebtedness or the covenants under the agreements governing our indebtedness; and adverse developments affecting the financial services industry. Additionally, forward-looking statements should be considered in conjunction with the cautionary statements contained in the risk factors disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 10-K for the fiscal year ended January 25, 2026, filed with the SEC on March 23, 2026 as such risk factors may be amended, supplemented or superseded from time to time by other reports the Company files with the SEC. In light of the significant risks and uncertainties inherent in the forward-looking information included herein that may cause actual performance and results to differ materially from those predicted, any such forward-looking information should not be regarded as representations or guarantees by the Company of future performance or results, or that its objectives or plans will be achieved or that any of its operating expectations or financial forecasts will be realized. Reported results should not be considered an indication of future performance. Investors are cautioned not to place undue reliance on any forward-looking information contained herein, which reflect management’s analysis only as of the date hereof. These forward-looking statements speak only as of the date hereof. Except as required by law, the Company assumes no obligation to publicly release the results of any update or revision to any forward-looking statement that may be made to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated or future events, or otherwise.

Amounts reported in this press release are preliminary and subject to the finalization and filing of our unaudited financial results on Form 10-Q for the three months ended July 26, 2026. In the reported results, Q2’27 refers to the quarter ended July 26, 2026, Q1’27 refers to the quarter ended April 26, 2026 and Q2’26 refers to the quarter ended July 27, 2025. Reported amounts may not foot precisely due to rounding.

About Semtech

Semtech Corporation (Nasdaq: SMTC) is a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected IoT devices worldwide. Our global teams are committed to empowering solution architects and application developers to develop breakthrough products for the infrastructure, industrial and consumer markets. To learn more about Semtech technology, visit us at Semtech.com.

Semtech and the Semtech logo are registered trademarks or service marks of Semtech Corporation or its subsidiaries.

SMTC-F

 

SEMTECH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data)

(unaudited)

 

 

Q2’27

 

Q1’27

 

Q2’26

Net sales

$

341.9

 

 

$

291.0

 

 

$

257.6

 

Cost of sales

 

158.1

 

 

 

139.6

 

 

 

123.5

 

Gross profit

 

183.8

 

 

 

151.5

 

 

 

134.1

 

Operating expenses, net:

 

 

 

 

 

Product development and engineering

 

60.6

 

 

 

57.6

 

 

 

48.2

 

Selling, general and administrative

 

67.3

 

 

 

66.6

 

 

 

58.5

 

Intangible amortization

 

0.4

 

 

 

0.3

 

 

 

0.1

 

Restructuring

 

(0.3

)

 

 

1.2

 

 

 

1.5

 

Goodwill impairment

 

 

 

 

 

 

 

42.0

 

Total operating expenses, net

 

128.0

 

 

 

125.7

 

 

 

150.3

 

Operating income (loss)

 

55.8

 

 

 

25.8

 

 

 

(16.2

)

Interest expense

 

(2.0

)

 

 

(1.9

)

 

 

(5.2

)

Interest income

 

0.9

 

 

 

0.9

 

 

 

0.5

 

Non-operating (expense) income

 

(0.1

)

 

 

0.2

 

 

 

(1.3

)

Income (loss) before taxes and equity method income (loss)

 

54.7

 

 

 

25.1

 

 

 

(22.2

)

(Benefit) provision for income taxes

 

(101.4

)

 

 

0.1

 

 

 

4.8

 

Net income (loss) before equity method income (loss)

 

156.0

 

 

 

24.9

 

 

 

(27.0

)

Equity method income (loss)

 

4.1

 

 

 

1.6

 

 

 

(0.1

)

Net income (loss)

$

160.1

 

 

$

26.6

 

 

$

(27.1

)

 

 

 

 

 

 

Earnings (loss) per share:

 

 

 

 

 

Basic

$

1.72

 

 

$

0.29

 

 

$

(0.31

)

Diluted

$

1.59

 

 

$

0.27

 

 

$

(0.31

)

 

 

 

 

 

 

Weighted average number of shares used in computing earnings (loss) per share:

 

 

 

 

 

Basic

 

93.3

 

 

 

92.9

 

 

 

86.7

 

Diluted

 

100.8

 

 

 

98.0

 

 

 

86.7

 

 

SEMTECH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions)

(unaudited)

 

 

July 26, 2026

 

January 25, 2026

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

204.1

 

$

195.2

Accounts receivable, net

 

169.9

 

 

160.6

Inventories

 

170.8

 

 

195.7

Prepaid taxes

 

21.4

 

 

15.4

Assets held for sale

 

132.2

 

 

Other current assets

 

44.5

 

 

88.2

Total current assets

 

742.8

 

 

655.1

Non-current assets:

 

 

 

Property, plant and equipment, net

 

105.2

 

 

109.3

Deferred tax assets

 

139.6

 

 

34.2

Goodwill

 

478.2

 

 

457.9

Other intangible assets, net

 

44.6

 

 

40.0

Other assets

 

136.5

 

 

113.7

Total assets

$

1,647.0

 

$

1,410.3

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

68.2

 

$

84.1

Accrued liabilities

 

155.2

 

 

191.8

Current portion of long-term debt

 

143.4

 

 

Liabilities held for sale

 

70.7

 

 

Total current liabilities

 

437.4

 

 

275.9

Non-current liabilities:

 

 

 

Deferred tax liabilities

 

 

 

0.1

Long-term debt

 

349.4

 

 

491.2

Other long-term liabilities

 

111.4

 

 

93.3

Stockholders’ equity

 

748.9

 

 

549.7

Total liabilities & equity

$

1,647.0

 

$

1,410.3

 

SEMTECH CORPORATION

SUPPLEMENTAL CASH FLOW INFORMATION

(in millions)

(unaudited)

 

 

Q2’27

 

Q1’27

 

Q2’26

Net cash provided by operating activities

$

68.9

 

 

$

36.2

 

 

$

44.4

 

Net capital expenditures

 

(7.5

)

 

 

(8.2

)

 

 

(2.9

)

Free cash flow

$

61.4

 

 

$

28.0

 

 

$

41.5

 

 

SEMTECH CORPORATION

SUPPLEMENTAL INFORMATION: RECONCILIATION OF GAAP TO NON-GAAP RESULTS

(in millions)

(unaudited)

 

 

Q2’27

(in millions)

Signal Integrity

 

Analog Mixed

Signal and

Wireless

 

Total

Semiconductor

Products

 

IoT Systems and

Connectivity

 

Unallocated1

 

Total

Net sales

$

126.2

 

 

$

117.4

 

 

$

243.5

 

 

$

98.3

 

 

$

 

 

$

341.9

 

Segment cost of sales

 

43.8

 

 

 

46.8

 

 

 

90.6

 

 

 

64.9

 

 

 

2.6

 

 

 

158.1

 

Segment gross profit

$

82.4

 

 

$

70.5

 

 

$

153.0

 

 

$

33.4

 

 

$

(2.6

)

 

$

183.8

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment gross margin

 

65.3

%

 

 

60.1

%

 

 

62.8

%

 

 

34.0

%

 

NM2

 

 

Gross margin (GAAP)

 

 

53.8

%

Share-based compensation

 

 

0.2

%

Amortization of acquired technology

 

 

0.5

%

Adjusted gross margin (Non-GAAP)

 

 

54.5

%

Business held for sale3

 

 

5.2

%

Adjusted gross margin, excluding business held for sale (Non-GAAP)

 

 

59.7

%

 

Q1’27

(in millions)

Signal Integrity

 

Analog Mixed

Signal and

Wireless

 

Total

Semiconductor

Products

 

IoT Systems and

Connectivity

 

Unallocated1

 

Total

Net sales

$

102.0

 

 

$

100.8

 

 

$

202.8

 

 

$

88.3

 

 

$

 

 

$

291.0

 

Segment cost of sales

 

38.0

 

 

 

41.6

 

 

 

79.6

 

 

 

56.7

 

 

 

3.3

 

 

 

139.6

 

Segment gross profit

$

64.0

 

 

$

59.2

 

 

$

123.1

 

 

$

31.6

 

 

$

(3.3

)

 

$

151.5

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment gross margin

 

62.7

%

 

 

58.7

%

 

 

60.7

%

 

 

35.8

%

 

NM2

 

 

Gross margin (GAAP)

 

 

52.0

%

Share-based compensation

 

 

0.4

%

Amortization of acquired technology

 

 

0.6

%

Adjusted gross margin (Non-GAAP)

 

 

53.0

%

 

Q2’26

(in millions)

Signal Integrity

 

Analog Mixed

Signal and

Wireless

 

Total

Semiconductor

Products

 

IoT Systems and

Connectivity

 

Unallocated1

 

Total

Net sales

$

76.8

 

 

$

92.0

 

 

$

168.8

 

 

$

88.8

 

 

$

 

 

$

257.6

 

Segment cost of sales

 

28.9

 

 

 

37.5

 

 

 

66.4

 

 

 

53.7

 

 

 

3.4

 

 

 

123.5

 

Segment gross profit

$

47.9

 

 

$

54.6

 

 

$

102.4

 

 

$

35.1

 

 

$

(3.4

)

 

$

134.1

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment gross margin

 

62.4

%

 

 

59.3

%

 

 

60.7

%

 

 

39.5

%

 

NM2

 

 

Gross margin (GAAP)

 

 

52.1

%

Share-based compensation

 

 

0.2

%

Amortization of acquired technology

 

 

0.9

%

Adjusted gross margin (Non-GAAP)

 

 

53.2

%

 

1 Unallocated includes share-based compensation and amortization of acquired technology

2 Not meaningful

3 Adjustment for net sales of $48.1 million and adjusted gross profit of $10.9 million related to business held for sale as of Q2’27

 

SEMTECH CORPORATION

SUPPLEMENTAL INFORMATION: RECONCILIATION OF GAAP TO NON-GAAP RESULTS (CONTINUED)

(in millions)

(unaudited)

 

 

Q2’27

 

Q1’27

 

Q2’26

Product development and engineering (GAAP)

$

60.6

 

 

$

57.6

 

 

$

48.2

 

Share-based compensation

 

(4.5

)

 

 

(6.4

)

 

 

(3.4

)

Adjusted product development and engineering (Non-GAAP)

$

56.1

 

 

$

51.1

 

 

$

44.8

 

 

 

 

 

 

 

 

Q2’27

 

Q1’27

 

Q2’26

Selling, general and administrative (GAAP)

$

67.3

 

 

$

66.6

 

 

$

58.5

 

Share-based compensation

 

(18.7

)

 

 

(18.9

)

 

 

(13.3

)

Transaction and integration related costs, net

 

(0.7

)

 

 

(2.8

)

 

 

(1.2

)

Litigation costs, net

 

(1.3

)

 

 

(1.1

)

 

 

(0.4

)

Adjusted selling, general and administrative (Non-GAAP)

$

46.7

 

 

$

43.9

 

 

$

43.6

 

 

 

 

 

 

 

 

Q2’27

 

Q1’27

 

Q2’26

Operating expenses, net (GAAP)

$

128.0

 

 

$

125.7

 

 

$

150.3

 

Share-based compensation

 

(23.1

)

 

 

(25.3

)

 

 

(16.7

)

Intangible amortization

 

(0.4

)

 

 

(0.3

)

 

 

(0.1

)

Transaction and integration related costs, net

 

(0.7

)

 

 

(2.8

)

 

 

(1.2

)

Restructuring and other reserves, net

 

0.3

 

 

 

(1.2

)

 

 

(1.5

)

Litigation costs, net

 

(1.3

)

 

 

(1.1

)

 

 

(0.4

)

Goodwill impairment

 

 

 

 

 

 

 

(42.0

)

Adjusted operating expenses, net (Non-GAAP)

$

102.8

 

 

$

95.1

 

 

$

88.4

 

 

Q2’27

 

Q1’27

 

Q2’26

Operating income (loss) (GAAP)

$

55.8

 

 

$

25.8

 

$

(16.2

)

Share-based compensation

 

23.8

 

 

 

26.4

 

 

17.3

 

Intangible amortization

 

2.3

 

 

 

2.1

 

 

2.4

 

Transaction and integration related costs, net

 

0.7

 

 

 

2.8

 

 

1.2

 

Restructuring and other reserves, net

 

(0.3

)

 

 

1.2

 

 

1.5

 

Litigation costs, net

 

1.3

 

 

 

1.1

 

 

0.4

 

Goodwill impairment

 

 

 

 

 

 

42.0

 

Adjusted operating income (Non-GAAP)

$

83.6

 

 

$

59.3

 

$

48.6

 

 

Q2’27

 

Q1’27

 

Q2’26

Operating margin (GAAP)

16.3

%

 

8.9

%

 

(6.3

)%

Share-based compensation

7.0

%

 

9.1

%

 

6.7

%

Intangible amortization

0.7

%

 

0.7

%

 

0.9

%

Transaction and integration related costs, net

0.2

%

 

0.9

%

 

0.5

%

Restructuring and other reserves, net

(0.1

)%

 

0.4

%

 

0.6

%

Litigation costs, net

0.3

%

 

0.4

%

 

0.1

%

Goodwill impairment

%

 

%

 

16.3

%

Adjusted operating margin (Non-GAAP)

24.4

%

 

20.4

%

 

18.8

%

 

SEMTECH CORPORATION

SUPPLEMENTAL INFORMATION: RECONCILIATION OF GAAP TO NON-GAAP RESULTS (CONTINUED)

(in millions, except per share data)

(unaudited)

 

 

Q2’27

 

Q1’27

 

Q2’26

Interest expense, net (GAAP)

$

1.0

 

 

$

1.0

 

 

$

4.7

 

Amortization of deferred financing costs

 

(1.1

)

 

 

(1.1

)

 

 

(1.3

)

Write-off of deferred financing costs

 

(0.2

)

 

 

 

 

 

(0.4

)

Interest rate swap termination

 

 

 

 

 

 

 

1.0

 

Adjusted interest (income) expense, net (Non-GAAP)

$

(0.2

)

 

$

(0.1

)

 

$

4.1

 

 

Q2’27

 

Q1’27

 

Q2’26

Net income (loss) (GAAP)

$

160.1

 

 

$

26.6

 

 

$

(27.1

)

Adjustments to GAAP net income (loss):

 

 

 

 

 

Share-based compensation

 

23.8

 

 

 

26.4

 

 

 

17.3

 

Intangible amortization

 

2.3

 

 

 

2.1

 

 

 

2.4

 

Transaction and integration related costs, net

 

0.7

 

 

 

2.8

 

 

 

1.2

 

Restructuring and other reserves, net

 

(0.3

)

 

 

1.2

 

 

 

1.5

 

Litigation costs, net

 

1.3

 

 

 

1.1

 

 

 

0.4

 

Investment gains, net

 

 

 

 

(0.1

)

 

 

 

Amortization of deferred financing costs

 

1.1

 

 

 

1.1

 

 

 

1.3

 

Write-off of deferred financing costs

 

0.2

 

 

 

 

 

 

0.4

 

Interest rate swap termination

 

 

 

 

 

 

 

(1.0

)

Goodwill impairment

 

 

 

 

 

 

 

42.0

 

Total Non-GAAP adjustments before taxes

 

29.0

 

 

 

34.5

 

 

 

65.3

 

Associated tax effect

 

(115.6

)

 

 

(10.0

)

 

 

(1.7

)

Equity method (income) loss

 

(4.1

)

 

 

(1.6

)

 

 

0.1

 

Total of supplemental information, net of taxes

 

(90.6

)

 

 

22.9

 

 

 

63.7

 

Adjusted net income (Non-GAAP)

$

69.5

 

 

$

49.4

 

 

$

36.7

 

 

 

 

 

 

 

Diluted earnings (loss) per share (GAAP)

$

1.59

 

 

$

0.27

 

 

$

(0.31

)

Adjustments per above

 

(0.88

)

 

 

0.24

 

 

 

0.72

 

Adjusted diluted earnings per share (Non-GAAP)

$

0.71

 

 

$

0.51

 

 

$

0.41

 

 

 

 

 

 

 

Weighted-average number of shares used in computing diluted earnings (loss) per share:

 

 

 

 

 

GAAP

 

100.8

 

 

 

98.0

 

 

 

86.7

 

Non-GAAP

 

97.7

 

 

 

96.5

 

 

 

90.0

 

 

SEMTECH CORPORATION

SUPPLEMENTAL INFORMATION: RECONCILIATION OF GAAP TO NON-GAAP RESULTS (CONTINUED)

(in millions)

(unaudited)

 

 

Q2’27

 

Q1’27

 

Q2’26

Net income (loss) (GAAP)

$

160.1

 

 

$

26.6

 

 

$

(27.1

)

Interest expense

 

2.0

 

 

 

1.9

 

 

 

5.2

 

Interest income

 

(0.9

)

 

 

(0.9

)

 

 

(0.5

)

Non-operating expense (income), net

 

0.1

 

 

 

(0.2

)

 

 

1.3

 

(Benefit) provision for income taxes

 

(101.4

)

 

 

0.1

 

 

 

4.8

 

Equity method (income) loss

 

(4.1

)

 

 

(1.6

)

 

 

0.1

 

Share-based compensation

 

23.8

 

 

 

26.4

 

 

 

17.3

 

Depreciation and amortization

 

9.8

 

 

 

9.2

 

 

 

10.3

 

Transaction and integration related costs, net

 

0.7

 

 

 

2.8

 

 

 

1.2

 

Restructuring and other reserves, net

 

(0.3

)

 

 

1.2

 

 

 

1.5

 

Litigation costs, net

 

1.3

 

 

 

1.1

 

 

 

0.4

 

Goodwill impairment

 

 

 

 

 

 

 

42.0

 

Adjusted EBITDA (Non-GAAP)

$

91.1

 

 

$

66.4

 

 

$

56.5

 

 

Q2’27

 

Q1’27

 

Q2’26

Operating margin (GAAP)

16.3

%

 

8.9

%

 

(6.3

)%

Share-based compensation

7.0

%

 

9.1

%

 

6.7

%

Depreciation and amortization

2.9

%

 

3.1

%

 

4.0

%

Transaction and integration related costs, net

0.2

%

 

0.9

%

 

0.5

%

Restructuring and other reserves, net

(0.1

)%

 

0.4

%

 

0.6

%

Litigation costs, net

0.3

%

 

0.4

%

 

0.1

%

Goodwill impairment

%

 

%

 

16.3

%

Adjusted EBITDA margin (Non-GAAP)

26.6

%

 

22.8

%

 

21.9

%

 

Mitch Haws

Semtech Corporation

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Networks Internet Artificial Intelligence Technology Apps/Applications IOT (Internet of Things) Semiconductor

MEDIA:

Logo
Logo

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

SAN DIEGO–(BUSINESS WIRE)–
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET.

An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for major depressive disorder. For more information, please visit www.contineum-tx.com.

Steve Kunszabo

Contineum Therapeutics

Senior Director, Investor Relations & Corporate Communications

858-649-1158

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo

Coherent Corp. to Unveil PhotonLink™ Platform at ECOC on September 21, 2026

SAXONBURG, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR) (“Coherent,” “We,” or the “Company”), a global leader in photonics, announced today that it will unveil Coherent PhotonLink at the 2026 European Conference on Optical Communication (ECOC), Europe’s largest and most prestigious event for optical communications, fiber optics, and photonics.

Coherent PhotonLink™ is an unparalleled new platform for integrated optics spanning the complete optical signal chain from light generation and beam shaping through transmission, detection, and conversion back to an electrical signal for the xPU or switch chip. Coherent PhotonLink™ supports CPO, NPO, and other forms of optical integration. The groundbreaking new platform leverages the breadth of Coherent’s photonic technology portfolio and manufacturing capabilities to enable next-generation datacenter architectures that use optical links to achieve new levels of bandwidth, performance, and energy efficiency.

Event: Coherent PhotonLink™ Unveiling at ECOC 2026

Location: Gran Hotel Miramar, Paseo de Reding 22, 29016 Málaga, Spain

Date: Monday, September 21, 2026

Time: 6:30 PM CEST / 12:30 PM ET

In-Person Registration:

In-Person
(Please note that in-person attendance is subject to availability due to limited seating. Submitting the RSVP form does not guarantee admission. Confirmed attendees will receive a separate confirmation.)

Webcast Registration:

Webcast

Presentations by Coherent’s CEO Jim Anderson; EVP, Optical Components and CTO Dr. Julie Eng; and EVP, Semiconductor Devices Dr. Beck Mason will be delivered in person and via live webcast accessible through Coherent’s Investor Relations website at coherent.com/company/investor-relations.


About Coherent

Coherent is the global photonics leader. We harness photons to drive innovation. Industry leaders in the datacenter, communications, and industrial markets rely on Coherent’s world-leading technology to fuel their own innovation and growth.

Founded in 1971 and operating in more than 20 countries, Coherent brings the industry’s broadest, deepest technology stack; unmatched supply chain resilience; and global scale to help its customers solve their toughest technology challenges. For more information, please visit us at coherent.com.

Contact:

Paul Silverstein
Senior VP, Investor Relations
[email protected]



Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)

SPY072 was well tolerated with rates of adverse events comparable to placebo

Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoimmune disease and as combination components

Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in late 2027 or early 2028

WALTHAM, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced topline results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (ACR50). SPY072 was well tolerated, with a safety profile consistent with the TL1A class. The results provide proof-of-mechanism for TL1A in RA and support its potential in other autoimmune diseases and as a combination component, but did not meet the Company’s internal bar to prioritize advancement of SPY072 in RA.

“The SKYWAY trial was designed to explore the safety and efficacy of TL1A inhibition in a range of rheumatic diseases to identify opportunities for indication-leading products. The results today do not lead us to prioritize SPY072 as a monotherapy in RA. However, the favorable safety profile of TL1A inhibition alongside demonstrated efficacy across inflammatory bowel disease, HS, and now RA provide increased conviction that our long-acting TL1A antibodies have potential in a range of autoimmune diseases and as optimal combination components,” said Cameron Turtle, DPhil, Chief Executive Officer at Spyre. “We want to thank the patients, investigators, and site staff who participated in this study and look forward to results in PsA and axSpA next quarter. Additionally, we are excited to have initiated our SKYLIGHT trial of SPY072 in combination with IL-17A/F in HS, our fourth investigational combination of validated mechanisms in autoimmune indications with high unmet need.”

SKYWAY-RA efficacy results

SPY072 Low Dose demonstrated a statistically significant benefit compared to placebo on the primary endpoint (change from baseline in DAS28-CRP) at Week 12. Nominally significant improvements versus placebo were observed on the secondary endpoint (ACR20) with High Dose and on the exploratory endpoint (ACR50) with Low Dose. Results were generally comparable between advanced-therapy-naïve and advanced-therapy-experienced sub-groups.

Endpoint (W12) SPY072 High Dose

(N=48)
SPY072 Low Dose

(N=48)
Placebo

(N=47)
ΔDAS28-CRP -1.5 -1.9* -1.3
ACR20 63%** 58% 43%
ACR50 31% 38%** 19%
ACR70 13% 4% 2%

*p<0.05 for SPY072 versus placebo        **nominal p<0.05 for SPY072 versus placebo

Both doses of SPY072 achieved target drug concentrations and provided complete and durable suppression of free TL1A through Week 12, suggesting complete target engagement.

Safety results

SPY072 was well tolerated with a safety profile consistent with the TL1A class. Rates of adverse events were comparable between active (27%) and placebo (36%) and generally mild or moderate. One Serious TEAE occurred on each arm, none deemed drug-related. One death occurred in a participant receiving placebo. The most common TEAEs were infections and infestations, occurring in 14% of SPY072-treated participants and 15% of placebo-treated participants.

Next steps

The Company remains at the forefront of evaluating potential first- and best-in-class monotherapies and combinations in I&I with numerous expected topline readouts over the next 12-18 months to prioritize programs for further development:

Trial Indication Asset(s) Expected timing
SKYLINE Part A Ulcerative Colitis SPY003 Sept 2026
SKYWAY PsA, axSpA SPY072 4Q 2026
SKYLINE Part B Ulcerative Colitis SPY001, SPY002, SPY003
SPY120, SPY130, SPY230
2027
SKYLIGHT HS SPY072 + IL-17A/F Late 2027 or early 2028



About SKYWAY-RA

The SKYWAY-RA sub-study is one of three sub-studies in the SKYWAY basket trial (NCT07148414) and is a randomized and placebo-controlled study evaluating two doses of SPY072 in patients with moderate to severely active RA with inadequate response to conventional or advanced therapies. The primary endpoint is the change from baseline to Week 12 in Disease Activity Score in 28 joints, C-reactive protein (DAS28-CRP) and the secondary endpoint is the proportion of patients achieving an ACR20 response at Week 12.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, visit Spyre’s website at www.spyre.com.

Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding: Spyre’s ability to achieve the expected benefits or opportunities with respect to its product candidates and combinations thereof, including its ability to develop next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the efficacy and safety of SPY072/ our TL1A antibodies and their broad potential in autoimmune diseases and as optimal combination components; the Company remaining at the forefront of evaluating potential first and best-in-class monotherapies and combinations in I&I; the expected timing of topline results from the PsA and axSpA SKYWAY sub-studies, SKYLIGHT trial in HS and SKYLINE part A and B in UC and the potential further development of these programs; the timing of and the Company’s ongoing development programs in inflammatory bowel disease and HS; and Spyre’s ongoing and future pre-clinical and clinical development activities. The words “opportunity,” “potential,” “milestones,” “pipeline,” “strategy,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “might,” “plan,” “possible,” “predict,” “should,” “will,” “would,” “can, ” “likely,” “aim,” and similar expressions (including the negatives of these terms) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs and involve a number of risks and uncertainties, many of which are beyond Spyre’s control, and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described in Spyre’s most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and any other filings that Spyre has made or may make with the Securities and Exchange Commission from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.

For Investors:     
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
[email protected] 

For Media:     
Josie Butler, 1AB
[email protected] 



Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital.

“This long-term data reinforces the benefits seen in clinical trials of once-weekly TransCon CNP, which have ranged from durable improvements in height to improvements in lower-extremity alignment, body proportionality, spinal canal dimensions, muscle function, and physical functioning – with a safety and tolerability profile similar to placebo and a low rate of injection site reactions,” said Aimee Shu, Executive Vice President, Chief Medical Officer at Ascendis Pharma. “The results align with improvements in health-related quality of life identified as important to the achondroplasia community and we look forward to sharing them with experts focused on advancing treatment of individuals living with skeletal dysplasia.”

Ascendis presentations at ISDS 2026 include:

ORAL PRESENTATION
Friday
August 28
10:00-10:15am
Session 4

Abstract #45
Improved Growth and Physical Functioning in Children with Achondroplasia Treated with Navepegritide in the ApproaCH Trial Open-Label Extension
Presented by Carlos Bacino, M.D.

POSTER  
Wednesday – Saturday
August 26-29
Poster Boards

Number Needed to Harm Analysis for Injection Site Reactions When Indirect Treatment Comparison (ITC) Is Not Suitable

Authors: Manoj Chevli et al

   

About TransCon CNP

TransCon CNP is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. In February 2026, TransCon CNP was approved by the U.S. Food & Drug Administration (FDA) under the trade name YUVIWEL® to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

About Achondroplasia

Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S

Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ planned oral presentation and poster at ISDS 2026, (ii) the benefits seen in clinical trials of once-weekly TransCon CNP, including durable improvements in height, lower-extremity alignment, body proportionality, spinal canal dimensions, muscle function, and physical functioning, (iii) the safety and tolerability profile of TransCon CNP, including a profile similar to placebo and a low rate of injection site reactions, (iv) the potential for the reported results to align with improvements in health-related quality of life identified as important to the achondroplasia community, (v) Ascendis’ clinical development activities, including the ApproaCH Trial open-label extension, (vi) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (vii) Ascendis’ use of TransCon to create new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YUVIWEL

®

are trademarks owned by the Ascendis Pharma group. © August 2026 Ascendis Pharma A/S. 

   

Investor Contacts:

Media Contact:
Chad Fugere Melinda Baker
Ascendis Pharma Ascendis Pharma
+1 (650) 519-7494 +1 (650) 709-8875
   



Wix to Participate in Fireside Chat at Citi’s 2026 Global Technology Conference

NEW YORK –
Wix.com Ltd. (NASDAQ: WIX), today announced that Wix management will participate in a fireside chat at Citi’s 2026 Global Technology Conference on Tuesday, September 8, 2026 at 2:35PM ET.

The event will be available via live audio webcast and archived replay on Wix’s investor relations website: https://investors.wix.com.

About Wix.com Ltd.

Wix’s vision is to simplify complex technologies and deliver the best tools for every type of user and business to create online. Powered by advanced AI and enterprise-grade infrastructure, Wix is trusted by millions of users worldwide. Founded in 2006 and strengthened by the acquisition in 2025 of Base44, the no-code application platform, Wix is continuing to build for the future of the internet.

For more about Wix, please visit our Press Room.
Media Relations Contact:  [email protected] 



Intuit Reports Fourth Quarter and Full Year Fiscal 2026 Results; Sets Fiscal 2027 Guidance

Intuit Reports Fourth Quarter and Full Year Fiscal 2026 Results; Sets Fiscal 2027 Guidance

Fourth-quarter revenue grew 14 percent, full year fiscal 2026 revenue grew 14 percent

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Intuit Inc. (Nasdaq: INTU) the global financial technology platform that makes Intuit TurboTax, Credit Karma, QuickBooks, Mailchimp, and Intuit Enterprise Suite, announced financial results for the fourth quarter and full fiscal year 2026, which ended July 31, 2026.

“We surpassed $20 billion in revenue for the full year with growth fueled by our Big Bets which collectively grew 34 percent and represented 30 percent of full-year revenue,” said Sasan Goodarzi, Intuit’s chairman and chief executive officer. “Our strategy is to win as an AI-driven expert platform by creating a financial system of intelligence that increasingly does the work for consumers, businesses, and accountants and helps them accomplish the outcomes that matter most. Looking ahead, we’re focused on scaling our Big Bets, accelerating customer growth, and making deliberate choices to create a stronger foundation for durable long-term growth.”

Financial Highlights

For the full year:

  • Total revenue increased 14 percent to $21.4 billion.

  • Global Business Solutions revenue increased 16 percent to $12.9 billion, and Online Ecosystem revenue increased 19 percent to $9.9 billion.

  • Consumer revenue increased 11 percent to $8.6 billion.

  • GAAP operating income increased 20 percent to $5.9 billion, and non-GAAP operating income increased 18 percent to $8.9 billion.

  • GAAP earnings per share increased 20 percent to $16.46, and non-GAAP earnings per share increased 20 percent to $24.27.

For the fourth quarter:

  • Total revenue increased 14 percent to $4.4 billion.

  • Global Business Solutions revenue increased 14 percent to $3.4 billion, and Online Ecosystem revenue increased 17 percent to $2.6 billion.

  • Consumer revenue increased 14 percent to $930 million.

Unless otherwise noted, all growth rates refer to the current period versus the comparable prior-year period, and the business metrics and associated growth rates refer to worldwide business metrics.

“Fiscal 2026 demonstrated the strength of our platform and the growing contribution of our Big Bets,” said Sandeep Aujla, Intuit’s chief financial officer. “As we look ahead, we are focused on execution and taking a disciplined approach to investments as we scale our Big Bets and accelerate customer growth. We remain committed to delivering durable revenue growth, operating margin expansion, and growing capital returns to shareholders over the long term.”

Business Segment Results

For the full year:

  • Global Business Solutions revenue increased 16 percent to $12.9 billion. Excluding Mailchimp, Global Business Solutions revenue increased 18 percent. Online Ecosystem revenue increased 19 percent to $9.9 billion. Excluding Mailchimp, Online Ecosystem revenue increased 23 percent.

    • QuickBooks Online Accounting revenue increased 23 percent.

    • Online Services revenue increased 16 percent. Excluding Mailchimp, Online Services revenue grew 24 percent.

    • Total international online revenue increased 10 percent on a constant currency basis.

  • Consumer revenue increased 11 percent to $8.6 billion.

    • TurboTax revenue increased 7 percent to $5.3 billion. TurboTax Live revenue increased 37 percent, representing 53 percent of total TurboTax revenue.

    • Credit Karma revenue increased 20 percent to $2.6 billion.

    • ProTax revenue increased 4 percent to $647 million.

TurboTax Federal Unit Data

Units in millions

Full Fiscal Year

2026

Full Fiscal Year

2025

Change

Year-Over-Year

Desktop Units

4.1

4.4

(7)%

Online Units

34.9

35.5

(2)%

Total U.S. TurboTax Units

39.0

39.9

(2)%

For the fourth quarter:

  • Global Business Solutions revenue increased 14 percent to $3.4 billion. Excluding Mailchimp, Global Business Solutions revenue increased 15 percent. Online Ecosystem revenue increased 17 percent to $2.6 billion. Excluding Mailchimp, Online Ecosystem revenue increased 20 percent.

    • QuickBooks Online Accounting revenue increased 20 percent driven by higher effective prices, customer growth, and mix shift.

    • Online Services revenue increased 15 percent driven by money and payroll. Excluding Mailchimp, Online Services revenue increased 21 percent.

    • Total international online revenue increased 10 percent on a constant currency basis.

  • Consumer revenue increased 14 percent to $930 million.

    • TurboTax revenue increased 3 percent to $153 million.

    • Credit Karma revenue increased 16 percent to $743 million driven by strength in personal loans, auto insurance, and credit cards.

    • ProTax revenue increased 6 percent to $34 million.

Capital Allocation Summary

  • Total cash and investments balance was $7.2 billion and total debt was $7.7 billion as of July 31, 2026. In June, we issued $1.75 billion in senior notes which further strengthens our liquidity to address debt maturing in fiscal 2027.

  • Intuit repurchased $5.5 billion of stock during fiscal year 2026, up 96 percent versus last year, and these repurchases drove a 2 percent reduction in weighted-average diluted shares outstanding as share repurchases more than offset dilution from share-based compensation. The company has a total remaining authorization of $7.9 billion to repurchase shares.

  • Intuit’s Board approved a quarterly dividend of $1.38 per share, payable on October 16, 2026. This represents a 15 percent increase versus last year.

Mailchimp Segment Reporting Change

Effective August 1, 2026, the company began managing Mailchimp as a separate operating segment from Global Business Solutions. Mailchimp will be a separate reportable segment beginning in fiscal 2027. Additional information can be found on the company’s fact sheet at https://investors.intuit.com/financial-information.

Non-GAAP Reporting Change

Effective August 1, 2026, share-based compensation expense will no longer be excluded from Intuit’s non-GAAP financial measures. The company views share-based compensation as a recurring component of the compensation program, and believes including this expense in non-GAAP financial measures reflects core operating results.

Forward-looking Guidance

Intuit announced guidance for the full year fiscal 2027 as well as the first quarter of fiscal 2027. All guidance reflects the Mailchimp segment reporting change as well as the non-GAAP reporting change noted above. The company expects:

Full Year Fiscal 2027 Guidance

 

GAAP

Non-GAAP

 

FY27

Change

FY27

Change

Total Revenue

$23,279 to $23,512

9% to 10%

 

 

Global Business Solutions

$13,068 to $13,158

13% to 14%

 

 

TurboTax

$5,377 to $5,453

2% to 3%

 

 

Credit Karma

$2,919 to $2,973

11% to 13%

 

 

ProTax

$659 to $662

2%

 

 

Consumer

$8,955 to $9,088

4% to 6%

 

 

Mailchimp

$1,256 to $1,266

(1)% to 0%

 

 

Operating Income

$7,408 to $7,490

26% to 27%

$8,063 to $8,145(1)

17% to 18%

Diluted Earnings Per Share

$20.12 to $20.36

22% to 24%

$22.88 to $23.12(1)

23% to 24%

 

Dollars are in millions, except earnings per share. See “About Non-GAAP Financial Measures” below for more information regarding financial measures not prepared in accordance with Generally Accepted Accounting Principles (GAAP).

 

(1) Non-GAAP operating income guidance includes $2,020 million from share-based compensation expense, and non-GAAP diluted earnings per share guidance includes a $5.81 impact from share-based compensation expense.

First Quarter Fiscal 2027 Guidance

 

GAAP

Non-GAAP

 

Q1FY27

Change

Q1FY27

Change

Total Revenue

$4,294 to $4,313

11%

 

 

Operating Income

$716 to $729

34% to 37%

$902 to $915(1)

26% to 28%

Diluted Earnings Per Share

$1.71 to $1.75

8% to 10%

$2.44 to $2.48(1)

30% to 33%

 

Dollars are in millions, except earnings per share. See “About Non-GAAP Financial Measures” below for more information regarding financial measures not prepared in accordance with Generally Accepted Accounting Principles (GAAP).

 

(1) Non-GAAP operating income guidance includes $521 million from share-based compensation expense, and non-GAAP diluted earnings per share guidance includes a $1.48 impact from share-based compensation expense.

Conference Call Details

Intuit executives will discuss the financial results on a conference call at 1:30 p.m. Pacific time on August 25. The conference call can be heard live at https://investors.intuit.com/news-events/ir-calendar. Prepared remarks for the call will be available on Intuit’s website after the call ends.

Investor Day 2027

Intuit will host its annual Investor Day on September 17 at 8:00 a.m. Pacific time, at its headquarters in Mountain View, CA. The event can be viewed live at https://investors.intuit.com/news-events/ir-calendar and a replay will be available on the Intuit Investor Relations website. The half-day event will include presentations from Sasan Goodarzi, chief executive officer, Sandeep Aujla, chief financial officer, and other leaders.

About Intuit

Intuit is the global financial technology platform that powers prosperity for the people and communities we serve. With approximately 100 million customers worldwide using products such as TurboTax, Credit Karma, QuickBooks, and Mailchimp, and Intuit Enterprise Suite, we believe that everyone should have the opportunity to prosper. We never stop working to find new, innovative ways to make that possible. Please visit us at Intuit.com and find us on social for the latest information about Intuit and our products and services.

About Non-GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles, please see the section of the accompanying tables titled “About Non-GAAP Financial Measures” as well as the related Table B1, Table B2, and Table E. A copy of the press release issued by Intuit today can be found on the investor relations page of Intuit’s website.

Cautions About Forward-looking Statements

This press release contains forward-looking statements, including expectations regarding: forecasts and timing of growth and future financial results of Intuit and its reporting segments; Intuit’s prospects for the business in fiscal 2027 and beyond; Intuit’s growth outside the US; timing and growth of revenue from current or future products, features, and services; innovation across our ecosystem; demand for our products; customer growth and retention; Intuit’s corporate tax rate; changes to our products, including the impact of artificial intelligence (AI); the amount and timing of any future dividends or share repurchases; our capital structure; our share-based compensation expense; availability of our offerings; and the impact of strategic decisions on our business; as well as all of the statements under the heading “Forward-looking Guidance.”

Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause our actual results to differ materially from the expectations expressed in the forward-looking statements. These risks and uncertainties may be amplified by the effects of global developments and conditions or events, including macroeconomic uncertainty and geopolitical conditions, which have caused significant global economic instability and uncertainty. Given these risks and uncertainties, persons reading this communication are cautioned not to place any undue reliance on such forward-looking statements. These factors include, without limitation, the following: our ability to realize the anticipated benefits of our restructuring plan (Plan); risks related to the preliminary nature of the estimate of the charges to be incurred in connection with the Plan, which is subject to change; risks related to any delays in the timing for implementing the Plan or potential disruptions to our business or operations as we execute on the Plan; our ability to compete successfully; potential governmental encroachment in our tax business; our ability to develop, deploy, and use AI in our platform and offerings; our ability to adapt to technological change and to successfully extend our platform; our ability to predict consumer behavior; our ability to anticipate and solve new and existing customer problems; our reliance on intellectual property; our ability to protect our intellectual property rights; any harm to our reputation; risks associated with our environmental, social, and governance efforts; risks associated with acquisition and divestiture activity; the issuance of equity or incurrence of debt to fund acquisitions or for general business purposes; cybersecurity incidents (including those affecting the third parties we rely on); customer or regulator concerns about privacy and cybersecurity incidents; fraudulent activities by third parties, including through the use of AI; our failure to process transactions effectively; interruption or failure of our information technology; our ability to maintain critical third-party business relationships; our ability to attract and retain talent and the success of our hybrid work model; our ability to effectively develop and deploy AI in our offerings; any deficiency in the quality or accuracy of our offerings (including the advice given by experts on our platform); any delays in product launches; difficulties in processing or filing customer tax submissions; risks associated with international operations; risks associated with climate change; changes to, and evolving interpretations of public policy, laws, or regulations affecting our businesses; allegations of legal claims and legal proceedings in which we are involved; fluctuations in the results of our tax business due to seasonality and other factors beyond our control; changes in tax rates and tax reform legislation; global economic conditions (including, without limitation, inflation); exposure to credit, counterparty, and other risks in providing capital to businesses; amortization of acquired intangible assets and impairment charges; our ability to repay or otherwise comply with the terms of our outstanding debt; our ability to repurchase shares or distribute dividends; volatility of our stock price; and our ability to successfully market our offerings.

More details about these and other risks that may impact our business are included in our Form 10-K for fiscal 2025 and in our other SEC filings. You can locate these reports through our website at https://investors.intuit.com. First-quarter and full-year fiscal 2027 guidance speaks only as of the date it was publicly issued by Intuit. Other forward-looking statements represent the judgment of the management of Intuit as of the date of this presentation. Except as required by law, we do not undertake any duty to update any forward-looking statement or other information in this presentation.

 

TABLE A

INTUIT INC.

GAAP CONSOLIDATED STATEMENTS OF OPERATIONS

(In millions, except per share amounts)

(Unaudited)

 

 

Three Months Ended

 

Twelve Months Ended

 

July 31,

2026

 

July 31,

2025

 

July 31,

2026

 

July 31,

2025

 

 

 

 

 

 

 

 

Net revenue:

 

 

 

 

 

 

 

Service

$

3,783

 

 

$

3,291

 

 

$

18,911

 

 

$

16,400

 

Product and other

 

571

 

 

 

540

 

 

 

2,537

 

 

 

2,431

 

Total net revenue

 

4,354

 

 

 

3,831

 

 

 

21,448

 

 

 

18,831

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of revenue:

 

 

 

 

 

 

 

Cost of service revenue

 

894

 

 

 

834

 

 

 

4,016

 

 

 

3,624

 

Cost of product and other revenue

 

16

 

 

 

16

 

 

 

63

 

 

 

68

 

Amortization of acquired technology

 

43

 

 

 

44

 

 

 

174

 

 

 

156

 

Selling and marketing

 

1,264

 

 

 

1,251

 

 

 

5,534

 

 

 

5,035

 

Research and development

 

857

 

 

 

801

 

 

 

3,376

 

 

 

2,928

 

General and administrative

 

391

 

 

 

424

 

 

 

1,623

 

 

 

1,601

 

Amortization of other acquired intangible assets

 

121

 

 

 

121

 

 

 

485

 

 

 

481

 

Restructuring

 

293

 

 

 

1

 

 

 

293

 

 

 

15

 

Total costs and expenses [A]

 

3,879

 

 

 

3,492

 

 

 

15,564

 

 

 

13,908

 

Operating income

 

475

 

 

 

339

 

 

 

5,884

 

 

 

4,923

 

Interest expense

 

(70

)

 

 

(59

)

 

 

(256

)

 

 

(247

)

Interest and other income, net

 

135

 

 

 

86

 

 

 

389

 

 

 

158

 

Income before income taxes

 

540

 

 

 

366

 

 

 

6,017

 

 

 

4,834

 

Income tax (benefit) provision [B]

 

177

 

 

 

(15

)

 

 

1,451

 

 

 

965

 

Net income

$

363

 

 

$

381

 

 

$

4,566

 

 

$

3,869

 

 

 

 

 

 

 

 

 

Basic net income per share

$

1.34

 

 

$

1.36

 

 

$

16.53

 

 

$

13.82

 

Shares used in basic per share calculations

 

272

 

 

 

279

 

 

 

276

 

 

 

280

 

 

 

 

 

 

 

 

 

Diluted net income per share

$

1.34

 

 

$

1.35

 

 

$

16.46

 

 

$

13.67

 

Shares used in diluted per share calculations

 

272

 

 

 

282

 

 

 

277

 

 

 

283

 

 

See accompanying Notes.

INTUIT INC.

NOTES TO TABLE A

 

[A]

The following table summarizes the total share-based compensation expense that we recorded in operating income for the periods shown.

 

 

Three Months Ended

 

Twelve Months Ended

(In millions)

July 31,

2026

 

July 31,

2025

 

July 31,

2026

 

July 31,

2025

Cost of revenue

$

93

 

$

101

 

$

371

 

$

423

Selling and marketing

 

144

 

 

137

 

 

587

 

 

541

Research and development

 

174

 

 

159

 

 

706

 

 

629

General and administrative

 

96

 

 

93

 

 

392

 

 

375

Total share-based compensation expense

$

507

 

$

490

 

$

2,056

 

$

1,968

 

[B]

We recognized tax shortfalls on share-based compensation of $43 million in our provision for income taxes for the twelve months ended July 31, 2026. We recognized excess tax benefits on share-based compensation of $143 million in our provision for income taxes for the twelve months ended July 31, 2025.

 

Our effective tax rate for the twelve months ended July 31, 2026 was approximately 24%. This rate differed from the federal statutory rate of 21% primarily due to state income taxes and non-deductible share-based compensation, which were partially offset by the benefit we received from the federal research and experimentation credit.

 

Our effective tax rate for the twelve months ended July 31, 2025 was approximately 20%. Excluding certain tax benefits primarily related to share-based compensation, our effective tax rate was approximately 24%. This rate differed from the federal statutory rate of 21% primarily due to state income taxes and non-deductible share-based compensation, which were partially offset by the benefit we received from the federal research and experimentation credit.

 

In the current global tax policy environment, the U.S. and other domestic and foreign governments continue to consider, and in some cases enact, changes in corporate tax laws. As changes occur, we account for finalized legislation in the period of enactment.

 

TABLE B1

INTUIT INC.

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

TO MOST DIRECTLY COMPARABLE GAAP FINANCIAL MEASURES

(In millions, except per share amounts)

(Unaudited)

 

 

Fiscal 2026

 

Q1

 

Q2

 

Q3

 

Q4

 

Full Year

GAAP operating income (loss)

$

534

 

 

$

855

 

 

$

4,020

 

 

$

475

 

 

$

5,884

 

Amortization of acquired technology

 

44

 

 

 

44

 

 

 

43

 

 

 

43

 

 

 

174

 

Amortization of other acquired intangible assets

 

121

 

 

 

121

 

 

 

122

 

 

 

121

 

 

 

485

 

Restructuring

 

 

 

 

 

 

 

 

 

 

293

 

 

 

293

 

Net (gain) loss on executive deferred compensation plan liabilities

 

16

 

 

 

8

 

 

 

10

 

 

 

9

 

 

 

43

 

Share-based compensation expense

 

543

 

 

 

521

 

 

 

485

 

 

 

507

 

 

 

2,056

 

Non-GAAP operating income (loss)

$

1,258

 

 

$

1,549

 

 

$

4,680

 

 

$

1,448

 

 

$

8,935

 

 

 

 

 

 

 

 

 

 

 

GAAP net income (loss)

$

446

 

 

$

693

 

 

$

3,064

 

 

$

363

 

 

$

4,566

 

Amortization of acquired technology

 

44

 

 

 

44

 

 

 

43

 

 

 

43

 

 

 

174

 

Amortization of other acquired intangible assets

 

121

 

 

 

121

 

 

 

122

 

 

 

121

 

 

 

485

 

Restructuring

 

 

 

 

 

 

 

 

 

 

293

 

 

 

293

 

Net (gain) loss on executive deferred compensation plan liabilities

 

16

 

 

 

8

 

 

 

10

 

 

 

9

 

 

 

43

 

Share-based compensation expense

 

543

 

 

 

521

 

 

 

485

 

 

 

507

 

 

 

2,056

 

Net (gain) loss on debt securities and other investments [A]

 

(34

)

 

 

(29

)

 

 

(44

)

 

 

(67

)

 

 

(174

)

Net (gain) loss on executive deferred compensation plan assets

 

(15

)

 

 

(8

)

 

 

(9

)

 

 

(8

)

 

 

(40

)

Net (gain) loss on disposal of a business

 

 

 

 

 

 

 

(1

)

 

 

5

 

 

 

4

 

Income tax effects and adjustments [B]

 

(182

)

 

 

(190

)

 

 

(134

)

 

 

(169

)

 

 

(675

)

Non-GAAP net income (loss)

$

939

 

 

$

1,160

 

 

$

3,536

 

 

$

1,097

 

 

$

6,732

 

 

 

 

 

 

 

 

 

 

 

GAAP diluted net income (loss) per share

$

1.59

 

 

$

2.48

 

 

$

11.09

 

 

$

1.34

 

 

$

16.46

 

Amortization of acquired technology

 

0.16

 

 

 

0.16

 

 

 

0.16

 

 

 

0.16

 

 

 

0.63

 

Amortization of other acquired intangible assets

 

0.43

 

 

 

0.43

 

 

 

0.44

 

 

 

0.44

 

 

 

1.75

 

Restructuring

 

 

 

 

 

 

 

 

 

 

1.08

 

 

 

1.06

 

Net (gain) loss on executive deferred compensation plan liabilities

 

0.05

 

 

 

0.03

 

 

 

0.04

 

 

 

0.03

 

 

 

0.15

 

Share-based compensation expense

 

1.93

 

 

 

1.86

 

 

 

1.76

 

 

 

1.86

 

 

 

7.42

 

Net (gain) loss on debt securities and other investments [A]

 

(0.12

)

 

 

(0.10

)

 

 

(0.16

)

 

 

(0.25

)

 

 

(0.63

)

Net (gain) loss on executive deferred compensation plan assets

 

(0.05

)

 

 

(0.03

)

 

 

(0.03

)

 

 

(0.03

)

 

 

(0.14

)

Net (gain) loss on disposal of a business

 

 

 

 

 

 

 

(0.01

)

 

 

0.02

 

 

 

0.01

 

Income tax effects and adjustments [B]

 

(0.65

)

 

 

(0.68

)

 

 

(0.49

)

 

 

(0.62

)

 

 

(2.44

)

Non-GAAP diluted net income (loss) per share

$

3.34

 

 

$

4.15

 

 

$

12.80

 

 

$

4.03

 

 

$

24.27

 

 

 

 

 

 

 

 

 

 

 

Shares used in GAAP diluted per share calculations

 

281

 

 

 

280

 

 

 

276

 

 

 

272

 

 

 

277

 

 

 

 

 

 

 

 

 

 

 

Shares used in non-GAAP diluted per share calculations

 

281

 

 

 

280

 

 

 

276

 

 

 

272

 

 

 

277

 

[A]

During the three months ended October 31, 2025, January 31, 2026, April 30, 2026, and July 31, 2026, we recognized $34 million, $31 million, $46 million, and $69 million, respectively, in net gains on other long-term investments.
 

[B]

As discussed in “About Non-GAAP Financial Measures – Income Tax Effects and Adjustments” following Table E, our long-term non-GAAP tax rate eliminates the effects of non-recurring and period-specific items. Income tax adjustments consist primarily of the tax impact of the non-GAAP pre-tax adjustments and tax effects related to share-based compensation.
 

See “About Non-GAAP Financial Measures” immediately following Table E for information on these measures, the items excluded from the most directly comparable GAAP measures in arriving at non-GAAP financial measures, and the reasons management uses each measure and excludes the specified amounts in arriving at each non-GAAP financial measure.

 

TABLE B2

INTUIT INC.

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

TO MOST DIRECTLY COMPARABLE GAAP FINANCIAL MEASURES

(In millions, except per share amounts)

(Unaudited)

 

 

Fiscal 2025

 

Q1

 

Q2

 

Q3

 

Q4

 

Full Year

GAAP operating income (loss)

$

271

 

 

$

593

 

 

$

3,720

 

 

$

339

 

 

$

4,923

 

Amortization of acquired technology

 

37

 

 

 

37

 

 

 

38

 

 

 

44

 

 

 

156

 

Amortization of other acquired intangible assets

 

120

 

 

 

120

 

 

 

120

 

 

 

121

 

 

 

481

 

Restructuring

 

9

 

 

 

4

 

 

 

1

 

 

 

1

 

 

 

15

 

Professional fees for business combinations

 

 

 

 

 

 

 

2

 

 

 

 

 

 

2

 

Net (gain) loss on executive deferred compensation plan liabilities

 

5

 

 

 

8

 

 

 

(7

)

 

 

21

 

 

 

27

 

Share-based compensation expense

 

511

 

 

 

498

 

 

 

469

 

 

 

490

 

 

 

1,968

 

Non-GAAP operating income (loss)

$

953

 

 

$

1,260

 

 

$

4,343

 

 

$

1,016

 

 

$

7,572

 

 

 

 

 

 

 

 

 

 

 

GAAP net income (loss)

$

197

 

 

$

471

 

 

$

2,820

 

 

$

381

 

 

$

3,869

 

Amortization of acquired technology

 

37

 

 

 

37

 

 

 

38

 

 

 

44

 

 

 

156

 

Amortization of other acquired intangible assets

 

120

 

 

 

120

 

 

 

120

 

 

 

121

 

 

 

481

 

Restructuring

 

9

 

 

 

4

 

 

 

1

 

 

 

1

 

 

 

15

 

Professional fees for business combinations

 

 

 

 

 

 

 

2

 

 

 

 

 

 

2

 

Net (gain) loss on executive deferred compensation plan liabilities

 

5

 

 

 

8

 

 

 

(7

)

 

 

21

 

 

 

27

 

Share-based compensation expense

 

511

 

 

 

498

 

 

 

469

 

 

 

490

 

 

 

1,968

 

Net (gain) loss on debt securities and other investments [A]

 

42

 

 

 

3

 

 

 

2

 

 

 

(2

)

 

 

45

 

Net (gain) loss on executive deferred compensation plan assets

 

(4

)

 

 

(7

)

 

 

7

 

 

 

(20

)

 

 

(24

)

Income tax effects and adjustments [B]

 

(208

)

 

 

(196

)

 

 

(172

)

 

 

(260

)

 

 

(836

)

Non-GAAP net income (loss)

$

709

 

 

$

938

 

 

$

3,280

 

 

$

776

 

 

$

5,703

 

 

 

 

 

 

 

 

 

 

 

GAAP diluted net income (loss) per share

$

0.70

 

 

$

1.67

 

 

$

10.02

 

 

$

1.35

 

 

$

13.67

 

Amortization of acquired technology

 

0.13

 

 

 

0.13

 

 

 

0.13

 

 

 

0.16

 

 

 

0.55

 

Amortization of other acquired intangible assets

 

0.42

 

 

 

0.42

 

 

 

0.43

 

 

 

0.43

 

 

 

1.70

 

Restructuring

 

0.03

 

 

 

0.01

 

 

 

 

 

 

 

 

 

0.05

 

Professional fees for business combinations

 

 

 

 

 

 

 

0.01

 

 

 

 

 

 

0.01

 

Net (gain) loss on executive deferred compensation plan liabilities

 

0.02

 

 

 

0.03

 

 

 

(0.02

)

 

 

0.07

 

 

 

0.10

 

Share-based compensation expense

 

1.80

 

 

 

1.76

 

 

 

1.66

 

 

 

1.74

 

 

 

6.95

 

Net (gain) loss on debt securities and other investments [A]

 

0.15

 

 

 

0.01

 

 

 

0.01

 

 

 

(0.01

)

 

 

0.16

 

Net (gain) loss on executive deferred compensation plan assets

 

(0.02

)

 

 

(0.02

)

 

 

0.02

 

 

 

(0.07

)

 

 

(0.09

)

Income tax effects and adjustments [B]

 

(0.73

)

 

 

(0.69

)

 

 

(0.61

)

 

 

(0.92

)

 

 

(2.95

)

Non-GAAP diluted net income (loss) per share

$

2.50

 

 

$

3.32

 

 

$

11.65

 

 

$

2.75

 

 

$

20.15

 

 

 

 

 

 

 

 

 

 

 

Shares used in GAAP diluted per share calculations

 

283

 

 

 

283

 

 

 

282

 

 

 

282

 

 

 

283

 

 

 

 

 

 

 

 

 

 

 

Shares used in non-GAAP diluted per share calculations

 

283

 

 

 

283

 

 

 

282

 

 

 

282

 

 

 

283

 

[A]

During the three months ended October 31, 2024, we recognized a $42 million net loss on other long-term investments.
 

[B]

As discussed in “About Non-GAAP Financial Measures – Income Tax Effects and Adjustments” following Table E, our long-term non-GAAP tax rate eliminates the effects of non-recurring and period-specific items. Income tax adjustments consist primarily of the tax impact of the non-GAAP pre-tax adjustments and tax effects related to share-based compensation.
 

See “About Non-GAAP Financial Measures” immediately following Table E for information on these measures, the items excluded from the most directly comparable GAAP measures in arriving at non-GAAP financial measures, and the reasons management uses each measure and excludes the specified amounts in arriving at each non-GAAP financial measure.

 

TABLE C

INTUIT INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions)

(Unaudited)

 

 

July 31,

2026

 

July 31,

2025

 

 

 

 

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

4,705

 

$

2,884

Investments

 

2,495

 

 

1,668

Accounts receivable, net

 

625

 

 

530

Notes receivable held for investment

 

1,468

 

 

1,403

Notes receivable held for sale

 

179

 

 

Income taxes receivable

 

124

 

 

50

Prepaid expenses and other current assets

 

677

 

 

496

Current assets before funds receivable and amounts held for customers

 

10,273

 

 

7,031

Funds receivable and amounts held for customers

 

5,038

 

 

7,076

Total current assets

 

15,311

 

 

14,107

 

 

 

 

Long-term investments

 

248

 

 

94

Property and equipment, net

 

1,023

 

 

961

Operating lease right-of-use assets

 

609

 

 

541

Goodwill

 

13,981

 

 

13,980

Acquired intangible assets, net

 

4,642

 

 

5,302

Long-term deferred income tax assets

 

172

 

 

1,222

Other assets

 

800

 

 

751

Total assets

$

36,786

 

$

36,958

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Short-term debt

$

1,249

 

$

Accounts payable

 

873

 

 

792

Accrued compensation and related liabilities

 

1,068

 

 

858

Deferred revenue

 

1,072

 

 

1,019

Other current liabilities

 

863

 

 

625

Current liabilities before funds payable and amounts due to customers

 

5,125

 

 

3,294

Funds payable and amounts due to customers

 

5,038

 

 

7,076

Total current liabilities

 

10,163

 

 

10,370

 

 

 

 

Long-term debt

 

6,420

 

 

5,973

Long-term deferred income tax liabilities

 

239

 

 

20

Operating lease liabilities

 

667

 

 

597

Other long-term obligations

 

305

 

 

288

Total liabilities

 

17,794

 

 

17,248

 

 

 

 

Stockholders’ equity

 

18,992

 

 

19,710

Total liabilities and stockholders’ equity

$

36,786

 

$

36,958

 

TABLE D

INTUIT INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(Unaudited)

 

 

Twelve Months Ended

 

July 31,

2026

 

July 31,

2025

Cash flows from operating activities:

 

 

 

Net income

$

4,566

 

 

$

3,869

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation

 

187

 

 

 

172

 

Amortization of acquired intangible assets

 

659

 

 

 

637

 

Non-cash operating lease cost

 

106

 

 

 

75

 

Share-based compensation expense

 

2,056

 

 

 

1,968

 

Provision for expected credit losses

 

237

 

 

 

134

 

Deferred income taxes

 

1,279

 

 

 

(435

)

Other

 

(248

)

 

 

(7

)

Total adjustments

 

4,276

 

 

 

2,544

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

(95

)

 

 

(71

)

Income taxes receivable

 

(74

)

 

 

27

 

Prepaid expenses and other assets

 

(221

)

 

 

(283

)

Accounts payable

 

63

 

 

 

73

 

Accrued compensation and related liabilities

 

202

 

 

 

(64

)

Deferred revenue

 

51

 

 

 

142

 

Operating lease liabilities

 

(93

)

 

 

(77

)

Other liabilities

 

163

 

 

 

47

 

Total changes in operating assets and liabilities

 

(4

)

 

 

(206

)

Net cash provided by operating activities

 

8,838

 

 

 

6,207

 

Cash flows from investing activities:

 

 

 

Purchases of corporate and customer fund investments

 

(3,892

)

 

 

(2,363

)

Sales of corporate and customer fund investments

 

547

 

 

 

320

 

Maturities of corporate and customer fund investments

 

2,554

 

 

 

864

 

Purchases of property and equipment

 

(221

)

 

 

(124

)

Acquisitions of businesses, net of cash acquired

 

 

 

 

(184

)

Originations and purchases of notes receivable held for investment

 

(6,755

)

 

 

(3,992

)

Sales of notes receivable originally classified as held for investment

 

2,210

 

 

 

562

 

Principal repayments of notes receivable held for investment

 

4,253

 

 

 

2,706

 

Other

 

(108

)

 

 

(107

)

Net cash used in investing activities

 

(1,412

)

 

 

(2,318

)

Cash flows from financing activities:

 

 

 

Proceeds from issuance of long-term debt, net of discount and issuance costs

 

1,736

 

 

 

 

Repayments of debt

 

 

 

 

(500

)

Proceeds from borrowings under secured revolving credit facilities

 

186

 

 

 

429

 

Repayments on borrowings under secured revolving credit facilities

 

(230

)

 

 

 

Proceeds from issuance of stock under employee stock plans

 

180

 

 

 

398

 

Payments for employee taxes withheld upon vesting of restricted stock units

 

(709

)

 

 

(982

)

Cash paid for purchases of treasury stock

 

(5,412

)

 

 

(2,772

)

Dividends and dividend rights paid

 

(1,347

)

 

 

(1,189

)

Net change in funds receivable and funds payable and amounts due to customers

 

(2,086

)

 

 

3,107

 

Other

 

(7

)

 

 

(1

)

Net cash used in financing activities

 

(7,689

)

 

 

(1,510

)

Effect of exchange rates on cash, cash equivalents, restricted cash, and restricted cash equivalents

 

(2

)

 

 

3

 

Net increase (decrease) in cash, cash equivalents, restricted cash, and restricted cash equivalents

 

(265

)

 

 

2,382

 

Cash, cash equivalents, restricted cash, and restricted cash equivalents at beginning of period

 

9,481

 

 

 

7,099

 

Cash, cash equivalents, restricted cash, and restricted cash equivalents at end of period

$

9,216

 

 

$

9,481

 

 

 

 

 

Reconciliation of cash, cash equivalents, restricted cash, and restricted cash equivalents reported within the consolidated balance sheets to the total amounts reported on the consolidated statements of cash flows

 

 

 

Cash and cash equivalents

$

4,705

 

 

$

2,884

 

Restricted cash and restricted cash equivalents included in funds receivable and amounts held for customers

 

4,511

 

 

 

6,597

 

Total cash, cash equivalents, restricted cash, and restricted cash equivalents at end of period

$

9,216

 

 

$

9,481

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

Interest paid

$

295

 

 

$

284

 

 

 

 

 

Supplemental schedule of non-cash investing and financing activities:

 

 

 

Transfers of notes receivable originated or purchased as held for investment to held for sale

$

2,348

 

 

$

546

 

Retirement of treasury stock

$

27,006

 

 

$

 

 

TABLE E

INTUIT INC.

RECONCILIATION OF FORWARD-LOOKING GUIDANCE FOR NON-GAAP FINANCIAL MEASURES TO PROJECTED GAAP REVENUE, OPERATING INCOME, AND EPS

(In millions, except per share amounts)

(Unaudited)

 

 

Forward-Looking Guidance

 

GAAP

Range of Estimate

 

 

 

Non-GAAP

Range of Estimate

 

From

 

To

 

Adjmts

 

From

 

To

Three Months Ending October 31, 2026

 

 

 

 

 

 

 

 

 

Revenue

$

4,294

 

$

4,313

 

$

 

$

4,294

 

$

4,313

Operating income

$

716

 

$

729

 

$

186

[a]

$

902

 

$

915

Diluted earnings per share

$

1.71

 

$

1.75

 

$

0.73

[b]

$

2.44

 

$

2.48

 

 

 

 

 

 

 

 

 

 

Twelve Months Ending July 31, 2027

 

 

 

 

 

 

 

 

 

Revenue

$

23,279

 

$

23,512

 

$

 

$

23,279

 

$

23,512

Operating income

$

7,408

 

$

7,490

 

$

655

[c]

$

8,063

 

$

8,145

Diluted earnings per share

$

20.12

 

$

20.36

 

$

2.76

[d]

$

22.88

 

$

23.12

See “About Non-GAAP Financial Measures” immediately following Table E for information on these measures, the items excluded from the most directly comparable GAAP measures in arriving at non-GAAP financial measures, and the reasons management uses each measure and excludes the specified amounts in arriving at each non-GAAP financial measure. Beginning in the first quarter of fiscal 2027, our non-GAAP financial measures will no longer exclude share-based compensation expense. The GAAP and Non-GAAP financial measures above are inclusive of $521 million and $2.0 billion of share-based compensation expense for the three months ending October 31, 2026, and the twelve months ended July 31, 2027, respectively.

 

[a]

Reflects estimated adjustments for amortization of other acquired intangible assets of approximately $121 million; amortization of acquired technology of approximately $43 million; and restructuring charges of approximately $22 million.
 

[b]

Reflects estimated adjustments in item [a], income taxes related to these adjustments, and other income tax effects related to the use of the non-GAAP tax rate.
 

[c]

Reflects estimated adjustments for amortization of other acquired intangible assets of approximately $483 million; amortization of acquired technology of approximately $150 million; and restructuring charges of approximately $22 million.
 

[d]

Reflects estimated adjustments in item [c], income taxes related to these adjustments, and other income tax effects related to the use of the non-GAAP tax rate.

INTUIT INC.

ABOUT NON-GAAP FINANCIAL MEASURES

The accompanying press release dated August 25, 2026 contains non-GAAP financial measures. Table B1, Table B2, and Table E reconcile the non-GAAP financial measures in that press release to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures include non-GAAP operating income (loss), non-GAAP net income (loss), and non-GAAP diluted net income (loss) per share.

Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures do not reflect a comprehensive system of accounting, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies.

We compute non-GAAP financial measures using the same consistent method from quarter to quarter and year to year. We may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures. Beginning in the first quarter of fiscal 2027, our non-GAAP financial measures will no longer exclude share-based compensation expense. Share-based compensation is a recurring component of our compensation program, and we believe including this expense in our non-GAAP financial measures reflects our core operating results.

We exclude the following items from all of our non-GAAP financial measures:

  • Amortization of acquired technology

  • Amortization of other acquired intangible assets

  • Restructuring charges

  • Share-based compensation expense(1)
  • Gains and losses on executive deferred compensation plan liabilities

  • Goodwill and intangible asset impairment charges

  • Gains and losses on disposals of businesses and long-lived assets

  • Professional fees and transaction costs for business combinations

We also exclude the following items from non-GAAP net income (loss) and diluted net income (loss) per share:

  • Gains and losses on debt securities and other investments

  • Gains and losses on executive deferred compensation plan assets

  • Income tax effects and adjustments

  • Discontinued operations

(1) Historical results in Tables B1 and B2 exclude share-based compensation expense from our non-GAAP financial measures. Forward-looking guidance for fiscal 2027 in Table E includes share-based compensation expense in our non-GAAP financial measures.

We believe these non-GAAP financial measures provide meaningful supplemental information regarding Intuit’s operating results primarily because they exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization, our individual operating segments, or our senior management. Segment managers are not held accountable for share-based compensation expense, amortization, restructuring, or the other excluded items and, accordingly, we exclude these amounts from our measures of segment performance. We believe our non-GAAP financial measures also facilitate the comparison by management and investors of results for current periods and guidance for future periods with results for past periods.

The following are descriptions of the items we exclude from our non-GAAP financial measures.

Amortization of acquired technology and amortization of other acquired intangible assets. When we acquire a business in a business combination, we are required by GAAP to record the fair values of the intangible assets of the business and amortize them over their useful lives. Amortization of acquired technology in cost of revenue includes amortization of software and other technology assets of acquired businesses. Amortization of other acquired intangible assets in operating expenses includes amortization of assets such as customer and user relationships and trade names and logos.

Restructuring charges. This consists of costs incurred as a direct result of discrete strategic restructuring actions, including, but not limited to severance and other one-time termination benefits, and other costs, which are different in terms of size, strategic nature, and frequency than ongoing productivity and business improvements.

Share-based compensation expense. This consists of non-cash expenses for stock options, restricted stock units, and our Employee Stock Purchase Plan. When considering the impact of equity awards, we place greater emphasis on overall shareholder dilution rather than the accounting charges associated with those awards.

Gains and losses on executive deferred compensation plan liabilities. We exclude from our non-GAAP financial measures gains and losses on the revaluation of our executive deferred compensation plan liabilities.

Goodwill and intangible asset impairment charges. We exclude from our non-GAAP financial measures non-cash charges to adjust the carrying values of goodwill and other acquired intangible assets to their estimated fair values.

Gains and losses on disposals of businesses and long-lived assets. We exclude from our non-GAAP financial measures gains and losses on disposals of businesses and long-lived assets because they are unrelated to our ongoing business operating results.

Professional fees and transaction costs for business combinations. We exclude from our non-GAAP financial measures the professional fees we incur to complete business combinations. These include investment banking, legal, and accounting fees.

Gains and losses on debt securities and other investments. We exclude from our non-GAAP financial measures credit losses on available-for-sale debt securities and gains and losses on other investments.

Gains and losses on executive deferred compensation plan assets. We exclude from our non-GAAP financial measures gains and losses on the revaluation of our executive deferred compensation plan assets.

Income tax effects and adjustments. We use a long-term non-GAAP tax rate for evaluating operating results and for planning, forecasting, and analyzing future periods. This long-term non-GAAP tax rate excludes the income tax effects of the non-GAAP pre-tax adjustments described above, and eliminates the effects of non-recurring and period specific items which can vary in size and frequency. Based on our long-term projections, we are using a long-term non-GAAP tax rate of 24% for fiscal 2026 and fiscal 2027. This long-term non-GAAP tax rate could be subject to change for various reasons including significant acquisitions, changes in our geographic earnings mix, or fundamental tax law changes in major jurisdictions in which we operate. We will evaluate this long-term non-GAAP tax rate on an annual basis and whenever any significant events occur which may materially affect this rate.

Operating results and gains and losses on the sale of discontinued operations. From time to time, we sell or otherwise dispose of selected operations as we adjust our portfolio of businesses to meet our strategic goals. In accordance with GAAP, we segregate the operating results of discontinued operations as well as gains and losses on the sale of these discontinued operations from continuing operations on our GAAP statements of operations but continue to include them in GAAP net income or loss and net income or loss per share. We exclude these amounts from our non-GAAP financial measures.

The reconciliations of the forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in Table E include all information reasonably available to Intuit at the date of this press release. These tables include adjustments that we can reasonably predict. Events that could cause the reconciliation to change include acquisitions and divestitures of businesses, goodwill and other asset impairments, sales of available-for-sale debt securities and other investments, and disposals of businesses and long-lived assets.

Investors

Kendra Goodenough

Intuit Inc.

650-944-3663

[email protected]

Media

Kali Fry

Intuit Inc.

650-944-3036

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Finance Artificial Intelligence Data Management Accounting Professional Services Technology Fintech

MEDIA:

Logo
Logo

Lattice to Showcase Industrial FPGA Innovations at FPGAWorld Conference 2026

Lattice to Showcase Industrial FPGA Innovations at FPGAWorld Conference 2026

HILLSBORO, Ore.–(BUSINESS WIRE)–Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced its exhibition plan for the upcoming FPGAWorld Conference 2026, taking place on Sept. 8, 2026, in Stockholm, Sweden.

As part of the event, Lattice will deliver technical presentations and host a demo showcase focused on how its low power FPGA solutions are advancing Industrial IoT and sensor bridging applications.

  • Who: Lattice Semiconductor
  • What / When (GMT+2):
    • Tuesday, Sept. 8, 2026

    • Lattice Demo Showcase

    • Presentations (Track: 12:20 – 13:35, Room Brave 05)

      • “Solving Your Power Puzzle: Lattice FPGAs’ Path to Uncompromised Low Power”

      • “Practical Security Fundamentals for FPGA Engineers”

  • Where:
    • AFRY, Frösundaleden 2A, 169 70 Solna, Sweden

The FPGAWorld Conference is an international forum for researchers, engineers, teachers, students, and hackers. It covers topics such as complex analog/digital/software FPGA SoC systems, FPGA/ASIC-based products, educational and industrial cases, and more.

Supporting Resources

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable and platform firmware leader. We solve customer challenges from the Edge to the Cloud, in the growing Compute, Communications, Industrial, and Embedded markets. With the addition of AMI’s industry-leading, silicon-neutral platform firmware and infrastructure manageability solutions, Lattice now delivers the industry’s most complete secure management and control platform for cloud and AI data center infrastructure. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world. For more information about Lattice, please visit www.latticesemi.com and follow us via LinkedIn, X, YouTube, Facebook, WeChat, and Weibo.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

MEDIA CONTACT:

Sophia Hong

Lattice Semiconductor

503-268-8786

[email protected]

INVESTOR CONTACT:

Rick Muscha

Lattice Semiconductor

408-826-6000

[email protected]

KEYWORDS: Oregon Europe Sweden United States North America

INDUSTRY KEYWORDS: Data Management Semiconductor IOT (Internet of Things) Technology Software Internet Hardware

MEDIA:

Logo
Logo